Xuexiang Du. Research Associate Faculty in University of Maryland School of Medicine in the United States. He has a broad background in tumor immunology with 12 years of experience. He focuses on the molecular mechanisms of immune checkpoint molecules and their application in cancer immunotherapy to dissociate the undesired immunotherapy related adverse events (irAE) from the beneficial cancer immunotherapeutic effect. His recent two first author papers published on Cell Research were both selected as Sanofi-Cell Research Outstanding Research Article Award. He is also looking for novel immune regulatory pathways as potential immunotherapy targets for safer and improved immunotherapy.